Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.

Sildenafil Therapy and Exercise Tolerance in Idiopathic Pulmonary Fibrosis

Abstract

Idiopathic pulmonary fibrosis (IPF) is a form of idiopathic interstitial pneumonia characterized by temporally and spatially heterogeneous fibroblast proliferation and poor prognosis. No therapies have been shown in randomized clinical trials (RCT) to influence survival. Twenty-nine subjects were assigned randomly in a pilot study to a double-blind, placebo-controlled, RCT to test sildenafil in patients with IPF with forced vital capacity 40-90% and diffusing capacity 30-90% of predicted. During the 6-month experimental treatment period, patients underwent 6-min walk tests and estimation of dyspnea using the Borg scale at baseline (0 months), 3 months, and 6 months. Participants had moderate impairment of pulmonary function, and there were no significant differences between placebo (n = 15) and sildenafil (n = 14)-treated groups. Sildenafil did not significantly increase 6-min walk test distance (mean distance +/- SD after 6-month protocol: placebo 355 +/- 82 m, sildenafil 324 +/- 41 m; p = 0.256) nor did it lessen dyspnea after exercise (mean Borg score after 6-month protocol: placebo 3.4 +/- 1.6, sildenafil 4.1 +/- 2.3; p = 0.492). Adverse reactions were few and minor in nature. In this trial, sildenafil did not significantly increase 6-min walk test distance or decrease the Borg dyspnea index in patients with clinically typical IPF. This trial was registered at clinicaltrials.gov as NCT00359736.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00408-009-9209-8

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 18 references

Cited by

See all 96

Metadata

Authors
Jackson, R. M., Glassberg, M. K., Ramos, C. F., Bejarano, P. A., Butrous, G., & Gómez-Marín, O.
Affiliations
  • University of Miami (US)
  • Miami VA Healthcare System (US)
  • University of Kent (GB)
Corresponding author
Jackson, Robert M.
Venue
Lung
Published
2009-12-12
Volume
188
Issue
2
Pages
115-123
ISSN
  • 0341-2040 (ISSN-L)
  • 1432-1750
OpenAlex
W2029732141
Cited by
92
References
18
Citations by year
2026: 2 · 2025: 4 · 2024: 8 · 2023: 6 · 2022: 3 · 2021: 4 · 2020: 9 · 2019: 5 · 2018: 7 · 2017: 6 · 2016: 10 · 2015: 4 · 2014: 7 · 2013: 5 · 2012: 5
FWCI
3.35
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Lung (publishedVersion)
  • PubMed (publishedVersion)
Funders
Pfizer UK
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
Keywords
idiopathic pulmonary fibrosis, sildenafil, exercise tolerance, 6-minute walk test, dyspnea, Borg scale, lung function, phosphodiesterase-5 inhibitors
MeSH terms
Sildenafil Citrate, Aged, Aged, 80 and over, Double-Blind Method, Dyspnea, Exercise Test, Female, Humans, Male, Middle Aged, Phosphodiesterase Inhibitors, Pilot Projects, Piperazines, Pulmonary Diffusing Capacity, Purines, Sulfones, Time Factors, Vasodilator Agents, Vital Capacity, Treatment Outcome, Exercise Tolerance, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sildenafil Therapy and Exercise Tolerance in Idiopathic Pulmonary Fibrosis. https://app.cochat.ai/papers/10.1007/s00408-009-9209-8
The paper
Jackson, R. M., Glassberg, M. K., Ramos, C. F., Bejarano, P. A., Butrous, G., & Gómez-Marín, O. (2010). Sildenafil Therapy and Exercise Tolerance in Idiopathic Pulmonary Fibrosis. Lung. https://doi.org/10.1007/s00408-009-9209-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.